MX2016005488A - Vector hsv oncolitico. - Google Patents

Vector hsv oncolitico.

Info

Publication number
MX2016005488A
MX2016005488A MX2016005488A MX2016005488A MX2016005488A MX 2016005488 A MX2016005488 A MX 2016005488A MX 2016005488 A MX2016005488 A MX 2016005488A MX 2016005488 A MX2016005488 A MX 2016005488A MX 2016005488 A MX2016005488 A MX 2016005488A
Authority
MX
Mexico
Prior art keywords
hsv
ohsv
oncolitico
present
inventive
Prior art date
Application number
MX2016005488A
Other languages
English (en)
Other versions
MX379501B (es
Inventor
Uchida Hiroaki
COHEN Justus
C Glorioso Joseph Iii
Grandi Paola
Original Assignee
Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education filed Critical Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education
Publication of MX2016005488A publication Critical patent/MX2016005488A/es
Publication of MX379501B publication Critical patent/MX379501B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16645—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16661—Methods of inactivation or attenuation
    • C12N2710/16662—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16671—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un Virus oncolítico del Herpes Simple recombinante (oHSV) que comprende un ligante no-HSV específico para una molécula (proteína, lípido, o determinante de carbohidratos) presentes en la superficie de una célula (tal como una célula de cáncer) y una o más copias de una o más secuencias diana de microARN insertadas en uno o más loci de genes HSV, preferiblemente uno o más gen(es) HSV necesario para la replicación de HSV en las células normales (es decir, no cancerosas). La invención proporciona además las acciones y composiciones farmacéuticas que comprenden el oHSV inventivo y métodos para matar las células tumorales que emplean el oHSV inventivo.
MX2016005488A 2013-10-28 2014-10-28 Vector hsv oncolítico. MX379501B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361896497P 2013-10-28 2013-10-28
PCT/US2014/062676 WO2015066042A1 (en) 2013-10-28 2014-10-28 Oncolytic hsv vector

Publications (2)

Publication Number Publication Date
MX2016005488A true MX2016005488A (es) 2016-10-03
MX379501B MX379501B (es) 2025-03-11

Family

ID=53005031

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016005488A MX379501B (es) 2013-10-28 2014-10-28 Vector hsv oncolítico.
MX2021001158A MX2021001158A (es) 2013-10-28 2016-04-27 Vector hsv oncolitico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021001158A MX2021001158A (es) 2013-10-28 2016-04-27 Vector hsv oncolitico.

Country Status (17)

Country Link
US (5) US10201575B2 (es)
EP (3) EP3184641B1 (es)
JP (3) JP6588024B2 (es)
KR (2) KR102330183B1 (es)
CN (2) CN113717952A (es)
AU (1) AU2014342465B2 (es)
BR (1) BR112016009465A8 (es)
CA (1) CA2928956A1 (es)
DK (1) DK3184641T3 (es)
ES (2) ES2810800T3 (es)
IL (2) IL245312B (es)
MX (2) MX379501B (es)
NZ (1) NZ720021A (es)
PT (1) PT3184641T (es)
RU (1) RU2719190C2 (es)
SG (1) SG11201603119RA (es)
WO (1) WO2015066042A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020109389A1 (en) 2018-11-28 2020-06-04 Innovative Molecules Gmbh Helicase primase inhibitors for treating cancer in a combination therapy with oncolytic viruses

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011130749A2 (en) 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
BR112016009465A8 (pt) 2013-10-28 2018-01-30 Univ Pittsburgh Commonwealth Sys Higher Education vetor de hsv oncolítico.
EP3256570B1 (en) * 2015-02-11 2021-03-31 Alma Mater Studiorum -Universita' di Bologna Retargeted herpesvirus with a glycoprotein h fusion
US10612005B2 (en) 2016-01-08 2020-04-07 Replimune Limited Modified oncolytic virus
KR20180136435A (ko) * 2016-01-27 2018-12-24 온코루스, 인크. 종양 살상형 바이러스 벡터 및 그의 용도
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
US12590321B2 (en) 2016-03-19 2026-03-31 Exuma Biotech Corp. Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof
CU24649B1 (es) * 2016-03-19 2023-02-13 Exuma Biotech Corp Retrovirus recombinantes incompetentes de replicación para la transducción de linfocitos y expansión regulada de los mismos
RS60410B1 (sr) 2016-04-08 2020-07-31 Krystal Biotech Inc Kompozicije za upotrebu u metodama za tretman rana, poremećaja i bolesti kože
AU2016403583B2 (en) * 2016-04-22 2020-05-28 Immvira Co., Limited Construction of oncolytic herpes simplex viruses (oHSV) obligate vector and constructs for cancer therapy
CN115960966B (zh) * 2016-04-29 2026-02-06 复诺健生物科技加拿大有限公司 在癌细胞中具有增强复制的hsv载体
KR20190015544A (ko) * 2016-06-09 2019-02-13 알마마 테르 스투디오룸 유니베르시타‘ 디 볼로냐 변형된 당단백질 d를 갖는 헤르페스 바이러스
EP3469070B1 (en) 2016-06-09 2021-08-04 Alma Mater Studiorum - Università di Bologna Herpesvirus with modified glycoprotein b
WO2017211945A1 (en) 2016-06-09 2017-12-14 Alma Mater Studiorum Universita Di Bologna Herpesvirus with modified glycoprotein h for propagation in a cell
CN109475613B (zh) * 2016-06-14 2024-02-20 匹兹堡大学-属高等教育联邦体系 使癌细胞对胞毒免疫细胞攻击敏感的nkg2d活化配体蛋白表达
AU2017290828A1 (en) 2016-06-30 2019-01-24 Virogin Biotech Canada Ltd Pseudotyped oncolytic viral delivery of therapeutic polypeptides
CA3030003A1 (en) * 2016-07-08 2018-01-11 F1 Oncology, Inc. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US20200085890A1 (en) * 2016-07-29 2020-03-19 Ohio State Innovation Foundation Expression of pten-long with ocolytic viruses
GB201616365D0 (en) * 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
JP7724601B2 (ja) * 2017-02-03 2025-08-18 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 腫瘍溶解性ウイルス療法
WO2018161825A1 (zh) * 2017-03-09 2018-09-13 厦门大学 一种重组单纯疱疹病毒及其用途
US11612625B2 (en) * 2017-07-26 2023-03-28 Oncorus, Inc. Oncolytic viral vectors and uses thereof
WO2019032866A1 (en) * 2017-08-09 2019-02-14 Ohio State Innovation Foundation ONCOLYTIC VIRUS CARRYING E-CADHERIN AND USES THEREOF
GB201714430D0 (en) * 2017-09-07 2017-10-25 Micol Romain Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
EP3710018A4 (en) * 2017-11-16 2022-03-09 Virogin Biotech Canada Ltd ONCOLYTIC VIRUSES DECORATED BY A TARGETING FRACTION
EP3731850A4 (en) * 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
EP4008333A1 (en) * 2018-02-19 2022-06-08 Combined Therapeutics, Inc. Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
EP3781188A4 (en) * 2018-04-13 2022-03-02 2seventy bio, Inc. ADOPTIVE CELL THERAPY
US10786438B2 (en) 2018-04-27 2020-09-29 Krystal Biotech, Inc. Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
WO2019232379A1 (en) * 2018-05-31 2019-12-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Antigenically stealthed oncolytic viruses
KR101998793B1 (ko) * 2018-09-04 2019-07-10 의료법인 성광의료재단 재조합 단순 헤르페스 바이러스의 제조를 위한 벡터
CN111117973A (zh) * 2018-10-30 2020-05-08 中国科学院武汉病毒研究所 一种受microRNA调控的重组溶瘤肠道病毒71型及应用
EP3921334A1 (en) 2019-02-08 2021-12-15 Krystal Biotech, Inc. Compositions and methods for delivering cftr polypeptides
CN119410708A (zh) * 2019-06-10 2025-02-11 高级健康研究所 星状病毒复制子的方法和组合物
CA3157063A1 (en) 2019-10-10 2021-04-15 Oncorus, Inc. Dual viruses and dual oncolytic viruses and methods of treatment
AU2020374942A1 (en) * 2019-11-01 2022-05-26 University Of Houston System Oncolytic virotherapy with induced anti-tumor immunity
WO2021246815A1 (ko) * 2020-06-03 2021-12-09 주식회사 젠셀메드 Hvec의 세포외 도메인과 암세포 표적화 영역의 융합 단백질을 발현할 수 있는 발현 카세트를 가지는 재조합 헤르페스 심플렉스 바이러스 및 그 용도
KR102311895B1 (ko) 2020-06-12 2021-10-14 주식회사 젠셀메드 재표적화를 위한 변형된 당단백질 gH를 가지는 재조합 헤르페스 심플렉스 바이러스 및 그 용도
JP7235334B2 (ja) * 2020-11-26 2023-03-08 イムヴィラ・カンパニー・リミテッド 癌の治療に用いる腫瘍溶解性単純ヘルペスウイルス（ｏＨＳＶ）偏性ベクター及びその構築体の構築
BR112023020209A2 (pt) 2021-04-02 2023-12-19 Krystal Biotech Inc Genoma do vírus do herpes recombinante, vírus do herpes, composição farmacêutica, uso do vírus do herpes ou da composição farmacêutica, método para expressar, realçar, aumentar, ampliar e/ou suplementar os níveis de um polipeptídeo imunomodulatório, método para prover alívio profilático, paliativo ou terapêutico, e, método para tratar câncer
CN114010666B (zh) * 2021-10-22 2024-05-07 上海交通大学 溶瘤病毒、parp抑制剂及pd-1抗体在制备抗肿瘤药物中的应用
TW202342758A (zh) * 2022-01-29 2023-11-01 加拿大商復諾健生物科技加拿大有限公司 轉錄及轉譯雙重調節之溶瘤單純疱疹病毒載體
WO2024151990A1 (en) * 2023-01-13 2024-07-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Effective oncolytic herpes simplex virus vector retargeting
WO2024182737A1 (en) * 2023-03-01 2024-09-06 The Brigham And Women’S Hospital, Inc. Oncolytic viruses to treat brain cancer
CN117085049A (zh) * 2023-08-18 2023-11-21 复旦大学附属中山医院 溶瘤单疱病毒oHSV联合BET抑制剂JQ1在治疗恶性胶质瘤中的应用
WO2025212872A1 (en) * 2024-04-03 2025-10-09 University Of Southern California T-bet induces tumor cell apoptosis and its utility in cancer therapy

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244792A (en) 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
JPH0668B2 (ja) 1985-08-30 1994-01-05 財団法人化学及血清療法研究所 単純ヘルペスウイルス遺伝子が組込まれた組換えプラスミド
US5849572A (en) 1990-10-10 1998-12-15 Regents Of The University Of Michigan HSV-1 vector containing a lat promoter
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5879934A (en) 1992-07-31 1999-03-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
GB9415369D0 (en) 1994-07-29 1994-09-21 Lynxvale Ltd Mutant virus
US6261552B1 (en) 1997-05-22 2001-07-17 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus vectors
GB9700411D0 (en) 1997-01-10 1997-02-26 Univ London Eukaryotic gene expression cassette and uses thereof
AU8605598A (en) 1997-07-31 1999-02-22 University Of Pittsburgh Targeted hsv vectors
CA2315251A1 (en) 1997-12-17 1999-06-24 Immunex Corporation Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides
EP1002864A1 (en) 1998-11-10 2000-05-24 Universita' degli studi di Bologna HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections
US6897057B1 (en) * 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
GB9930418D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
EP1381280B1 (en) * 2001-03-27 2011-05-11 Catherex, Inc. Viral vectors and their use in therapeutic methods
DE60232742D1 (de) 2001-10-04 2009-08-06 Immunex Corp Ul16-bindungsprotein 4
KR100900249B1 (ko) 2001-12-07 2009-05-29 포항공과대학교 산학협력단 ＳＩＶｍａｃ239의 면역원성 플라스미드 및 이들을 함유한ＡＩＤＳ ＤＮＡ 백신
CA2476724A1 (en) 2002-03-01 2003-09-12 Sloan-Kettering Institute For Cancer Research Prevention of recurrence and metastasis of cancer
US8927251B2 (en) 2002-10-07 2015-01-06 The University Of Chicago Targeting of herpes simplex virus to specific receptors
US7473418B2 (en) * 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
AU2005302408B2 (en) 2004-10-28 2012-08-09 The Government of the United States of America as represented by the Department of Veterans Affairs Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
CA2609142C (en) 2005-05-27 2016-02-09 Fondazione Centro San Raffaele Del Monte Tabor Therapeutic gene vectors comprising mirna target sequences
US20080008686A1 (en) 2006-07-10 2008-01-10 The Brigham And Women's Hospital, Inc. Tetracycline repressor regulated oncolytic viruses
EP2144632B1 (en) 2007-05-09 2016-11-16 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Synthetic herpes simplex viruses type-1 for treatment of cancers
WO2008143875A1 (en) 2007-05-14 2008-11-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
WO2009111892A1 (en) * 2008-03-14 2009-09-17 Ottawa Health Research Institute Microrna mediated oncolytic targeting
NO2700405T3 (es) * 2008-05-29 2018-09-01
WO2009148488A2 (en) 2008-05-29 2009-12-10 The General Hospital Corporation Use of oncolytic herpes viruses for killing cancer stem cells
GB0810912D0 (en) 2008-06-13 2008-07-23 Inst Animal Health Ltd Vector
JP2012520085A (ja) 2009-03-13 2012-09-06 エーゲン、インコーポレイテッド 生物活性ｒｎａの送達のための組成物及び方法
US20130071430A1 (en) * 2010-04-09 2013-03-21 The University Of Tokyo Microrna-controlled recombinant vaccinia virus and use thereof
WO2011130749A2 (en) 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
WO2012006181A2 (en) 2010-06-29 2012-01-12 Mount Sinai School Of Medicine Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
US20130156808A1 (en) 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus
JP6726824B2 (ja) 2013-07-17 2020-07-22 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 効率的な遺伝子送達用途のための非毒性ｈｓｖベクター及びその製造のための補完細胞
BR112016009465A8 (pt) 2013-10-28 2018-01-30 Univ Pittsburgh Commonwealth Sys Higher Education vetor de hsv oncolítico.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020109389A1 (en) 2018-11-28 2020-06-04 Innovative Molecules Gmbh Helicase primase inhibitors for treating cancer in a combination therapy with oncolytic viruses

Also Published As

Publication number Publication date
JP7262134B2 (ja) 2023-04-21
CA2928956A1 (en) 2015-05-07
US10201575B2 (en) 2019-02-12
US20160250267A1 (en) 2016-09-01
AU2014342465B2 (en) 2018-03-08
IL245312B (en) 2020-02-27
EP3063279A4 (en) 2017-05-17
JP6588024B2 (ja) 2019-10-09
CN106068326A (zh) 2016-11-02
CN106068326B (zh) 2021-06-18
SG11201603119RA (en) 2016-05-30
EP3063279A1 (en) 2016-09-07
RU2016120618A (ru) 2017-12-06
MX2021001158A (es) 2021-04-28
JP6919912B2 (ja) 2021-08-18
CN113717952A (zh) 2021-11-30
IL245312A0 (en) 2016-06-30
US11883448B2 (en) 2024-01-30
ES2781852T3 (es) 2020-09-08
JP2016537020A (ja) 2016-12-01
EP3184641A1 (en) 2017-06-28
RU2719190C2 (ru) 2020-04-17
DK3184641T3 (da) 2020-08-03
RU2016120618A3 (es) 2018-05-22
US20170274025A1 (en) 2017-09-28
KR20160108301A (ko) 2016-09-19
US10172893B2 (en) 2019-01-08
US10576115B2 (en) 2020-03-03
NZ720021A (en) 2022-08-26
IL272480A (en) 2020-03-31
EP3063279B1 (en) 2020-01-01
EP3184641B1 (en) 2020-07-08
HK1225756A1 (en) 2017-09-15
KR20210145296A (ko) 2021-12-01
EP3778906A1 (en) 2021-02-17
KR102490462B1 (ko) 2023-01-19
US20210138007A1 (en) 2021-05-13
BR112016009465A2 (pt) 2017-10-03
AU2014342465A1 (en) 2016-06-02
WO2015066042A1 (en) 2015-05-07
IL272480B (en) 2021-06-30
BR112016009465A8 (pt) 2018-01-30
MX379501B (es) 2025-03-11
US20190262410A1 (en) 2019-08-29
JP2020058341A (ja) 2020-04-16
PT3184641T (pt) 2020-08-21
US20170035819A1 (en) 2017-02-09
EP3778906B1 (en) 2025-07-02
KR102330183B1 (ko) 2021-11-23
ES2810800T3 (es) 2021-03-09
JP2021180661A (ja) 2021-11-25
US10188686B2 (en) 2019-01-29

Similar Documents

Publication Publication Date Title
MX2016005488A (es) Vector hsv oncolitico.
CL2019003842A1 (es) Vectores virales recombinantes con tropismo modificado y usos de estos para la introducción dirigida de material genético a células humanas.
MX390848B (es) Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos.
CY1121591T1 (el) Ογκολυτικος ιος απλου ερπητα και θεραπευτικες χρησεις αυτου
PE20200006A1 (es) Nuevas moleculas de union antigeno biespecificas capaces de unirse especificamente cd40 y a fap
CO2020007046A2 (es) Plataformas de entrega crispr objetivo
SG10201901482XA (en) Oncolytic adenovirus encoding a b7 protein
BR112016025519A2 (pt) engenharia genética in vivo com vetores de adenovírus
AR080009A1 (es) Alteracion genomica objetivo utilizando nucleasas de dedos de zinc
CY1114483T1 (el) Νεα ρυθμιστικα στοιχεια
CR20170406A (es) Arni variante
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
NZ738689A (en) Engineered crispr-cas9 compositions and methods of use
MX2019014100A (es) Variantes de endonucleasas cblb, composiciones y metodos de uso.
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
WO2015051199A3 (en) Modified pseudomonas exotoxin a
EA201692318A1 (ru) Композиции и способы для ингибирования экспрессии гена альфа-1-антитрипсина
BR112016017736A2 (pt) métodos e produtos para produção e distribuição de ácido nucleico
ECSP10010287A (es) Vectores de virus oncolíticos de viruela
MX2017008504A (es) Vacuna para enfermedad de newcastle y de bursitis infecciosa (nd-ibd) en vector de hvt mejorada.
CY1123144T1 (el) Επαγωγη καρδιακης αναγεννησης μe microrna
MX2018003757A (es) Composiciones y metodos para producir celulas dendriticas.
MX2017011298A (es) Métodos para tratar cáncer que albergan la pérdida hemicigota de tp53.
MX2018001055A (es) Promotores para mejorar la expresion en poxvirus.
MX382997B (es) Composiciones y metodos para mejorar la expresion genetica de pklr.